NCT00967759撤回3 期
A Double Blind, Randomized, Multicenter Phase III Study Comparing 3 Formulations: Dose Fixed Combination of Bronpheniramine and Fenilefrine, Bronpheniramine Isolated and Fenilefrine Isolated, to Evaluate the Efficacy and Safety of the Treatment of the Inflammatory Symptoms of Upper Respiratory Tract, in Children Between 2 and 6 Years Old.
Ache Laboratorios Farmaceuticos S.A.1 个研究点 分布在 1 个国家开始时间: 2009年8月28日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 试验地点
- 1
- 主要终点
- Evaluate the clinical efficacy of the dose fixed combination and each drug, that compose it, isolated, regarding the respiratory symptoms improvement in superior air passages acute affection in children between 2 and 6 years old.
研究概览
简要总结
The primary outcome of this study is to evaluate the clinical efficacy of the dose fixed combination and each drug, that composes it, isolated, regarding the respiratory symptoms improvement in superior air passages acute affection in children between 2 and 6 years old.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 2 Years 至 6 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients between 2 and 6 years old, according to dosage information provided in the product package insert.
- •Patient with a relative available for observation of symptoms during the night.
- •Patients with acute symptoms of air passages jeopardizing, initiated, at least, 24 hours before patient inclusion in this protocol and, at most, in the 3 days before patient inclusion.
- •Patients facing at least a 7 points score in the addition of general symptoms (rhinorrhea, sneeze, itching, nose obstruction and coughing).
- •At least two symptoms must be moderated in scale, for specific evaluation.
- •Presence of fluid and/or sputum verified through a rhinoscopy.
排除标准
- •Children younger than 2 years old or a weight and/or height percentual inferior to
- •Children with corporal weight superior to 30Kg.
- •Suggestive signs of superior air passages bacterial infection to the rhinoscopy, otoscopy and oropharingoscopy.
- •Chronic oral breath with a 6 months history.
- •Presence of degree II and III of nasal septal deviation (in any region and in any nasal fossa) and/or presence of nasal polyp or other conditions that determine nasal obstruction.
- •Patients in a chronic medication treatment for allergy.
- •Patients with an asthma clinical history confirmed (diagnosed).
- •Personal preceding of nasal surgery that in the opinion of the investigator can influence in the resistance to the air nose flow.
- •Children older than 5 years old that are not registered in the school.
- •Children that don´t have vaccination notebook.
- •Patient that had used prohibited medication, during the established period before V0 - Randomization Visit (See Picture 1).
- •Hypersensitive history to the study drug or its components.
- •Patient that have participated in, during the last 12 months, study protocols (according to Resolution 251, dated of August, 7th 1997, item III, sub-item J, "Investigator Responsibility", its recommended that the same person does not be subject of a clinical study in a new project before have elapsed 1(one) year from previous study participation, unless there is a direct benefit to the study patient).
- •Relatives of sponsor´s or study site´s employee.
- •Patients with gastroesofagic reflux disease.
- •Presence of psychiatry diseases.
- •Presence of mental disorder of any etiology.
- •Renal and hepatic insufficiency.
- •Patient with current evidence of clinically significant diseases, of origin: hematopoietic, gastrointestinal, cardiovascular, hepatic, renal, neurological, endocrinological, psychiatric, self immune, pulmonary, or other that preclude, according to the investigator criteria, the subject participation.
- •Patients with genetic diseases.
- •Any finding of clinical observation (anamneses and physical evaluation) that be understood by the investigator as risk to the patient participation in the study.
- •Any finding of lab result that the investigator judges as a risk to the patient, considering the participation in the study.
- •Patients with AST and ALT levels higher than 20% related to the upper normal limits; total bilirubins with an increase of 10% related to the upper normal limits; fasting serum/blood glucose >99mg/dl or postprandial serum/blood glucose >140mg/dl; Hb <10g/dl ou Hb >15 g/dl; serum creatinine with levels over than 10% of upper limit; serum potassium under 3,5 mEq/L, or upper 5,1 mEq/L; serum sodium under 136 mEq/L, or upper 145 mEq/L.
- •Presence of hematogenous or meliceric, purulent or mucus purulent secretion, bulging or malformation (leporine lips and nasolabial fissure surgically corrected or not) in the region of the nasal vestibule.
研究组 & 干预措施
Decongex Plus
Experimental
干预措施: Bronpheniramine and fenilefrine (Decongex Plus) (Drug)
Bronpheniramine isolated
Active Comparator
干预措施: Bronpheniramine isolated (Drug)
Fenilefrine isolated
Active Comparator
干预措施: Fenilefrine isolated (Drug)
结局指标
主要结局
Evaluate the clinical efficacy of the dose fixed combination and each drug, that compose it, isolated, regarding the respiratory symptoms improvement in superior air passages acute affection in children between 2 and 6 years old.
时间窗: 04/2010
次要结局
- Use of co intervention for symptom relief during treatment(Assessed during the treatment in the diary and questioned by the Investigator at the visits)
- Evaluate the intensity of the symptoms during the treatment(Assessed during the treatment)
- Adverse effect appearance during the study and tolerability(Assessed during the treatment and at the final visit)
- Patient adherence to the treatment.(04/2010)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsHIV-1 InfectionNCT02607956Gilead Sciences657
已完成
3 期
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsHIV-1 InfectionNCT02607930Gilead Sciences631
已完成
3 期
Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected AdultsHIV-1/HBV Co-InfectionNCT03547908Gilead Sciences244
已完成
3 期
A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil AloneEssential HypertensionNCT01456169Takeda507
已完成
3 期
A Study of Ibuprofen 250 mg / Acetaminophen 500 mg Comparing The Antipyretic Effects in Healthy Male VolunteersFeverNCT02761980Pfizer290